Marker Therapeutics, Inc. (MRKR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Marker Therapeutics reported revenue of $3.5M, down 46.2% from $6.6M the year before. Net income was -$12.2M (a -343.0% net margin), or -$0.79 per diluted share. Operating margin was -363.5%. Operating activities generated -$12.0M of cash. At fiscal year end, Marker Therapeutics held $19.1M in total assets against $2.3M in total liabilities, including $16.1M of cash and equivalents.
Open the full interactive Marker Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Marker Therapeutics Key Stats
| Share Price | $0.92 |
|---|---|
| Market Cap | $17.8M |
| Revenue YoY Growth | -46.2% |
| 52-Week Range | $0.86 – $2.19 |
| Shares Outstanding | 19.3 million (basic, 2026 Q2) |
Marker Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $466,785 | $0 | $9.0M | $3.3M | $6.6M | $3.5M |
| Operating Income | -$28.9M | -$39.5M | -$29.9M | -$14.6M | -$11.1M | -$12.9M |
| Pre-Tax Income | -$28.7M | -$41.9M | -$29.9M | -$14.0M | -$10.7M | -$12.2M |
| Income Tax | — | — | — | $3,675 | $49,953 | -$15,156 |
| Net Income | -$28.7M | -$41.9M | -$29.9M | -$8.2M | -$10.7M | -$12.2M |
| Diluted EPS | -$6.10 | -$5.50 | -$3.58 | -$0.94 | -$1.19 | -$0.79 |
Marker Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.2M | $1.1M | $751,691 | $0 |
| Net Income | -$2.0M | -$1.7M | -$3.2M | -$1.8M |
| Diluted EPS | -$0.12 | -$0.11 | -$0.16 | -$0.09 |
Marker Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.4M | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Current Assets | $24.4M | $46.0M | $16.6M | $17.1M | $22.0M | $19.1M |
| Total Assets | $45.6M | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Current Liabilities | $6.4M | $12.9M | $7.8M | $3.1M | $3.5M | $2.3M |
| Total Liabilities | $18.3M | $24.1M | $14.8M | $3.1M | $3.5M | $2.3M |
| Shareholders' Equity | $27.3M | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
Marker Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$18.9M | -$27.3M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
| Cash From Investing | -$10.4M | -$3.1M | -$4.9M | $18.7M | — | — |
| Cash From Financing | $6.7M | $52.6M | $202,130 | $1.1M | $15.0M | $9.9M |
| Free Cash Flow | — | — | — | -$10.3M | — | — |
Figures from Marker Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Marker Therapeutics financials page for every line item.
Marker Therapeutics Company Profile
| Ticker | MRKR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001094038 |
Frequently Asked Questions
What was Marker Therapeutics' revenue in fiscal 2025?
Marker Therapeutics (MRKR) reported revenue of $3.5M for fiscal 2025.
What is Marker Therapeutics' annual revenue history?
Marker Therapeutics' annual revenue by fiscal year: 2020: $466,785; 2021: $0; 2022: $9.0M; 2023: $3.3M; 2024: $6.6M; 2025: $3.5M.
What was Marker Therapeutics' net income in fiscal 2025?
Marker Therapeutics reported net income of -$12.2M for fiscal 2025.
What was Marker Therapeutics' earnings per share (EPS) in fiscal 2025?
Marker Therapeutics' diluted EPS was -$0.79 for fiscal 2025 (adjusted for any later stock splits).
What was Marker Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Marker Therapeutics reported revenue of $0.
How many shares of Marker Therapeutics are outstanding?
Marker Therapeutics reported a weighted average of 19.3 million basic shares outstanding in 2026 Q2.
What is Marker Therapeutics' market cap?
Based on its latest closing price, Marker Therapeutics (MRKR) has a market capitalization of about $17.8M.
When does Marker Therapeutics' fiscal year end?
Marker Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Marker Therapeutics headquartered?
Marker Therapeutics lists its business address in Houston, Texas in its SEC filings.